<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006316.pub3" GROUP_ID="AIRWAYS" ID="418706042321052107" MERGED_FROM="" MODIFIED="2017-08-21 16:35:54 +0100" MODIFIED_BY="Emma Dennett" NOTES="&lt;p&gt;CJC Jan 12th&lt;/p&gt;&lt;p&gt;Thanks to Anne for the clarifications. This is now ready to proceed.&lt;/p&gt;&lt;p&gt;Chris&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;/p&gt;&lt;p&gt;CJC Edit of update Jan 2008&lt;/p&gt;&lt;p&gt;I am happy with this update and the conclusions drawn from the single new study. Are there comments to be inserted into the last 3 boxes of the Risk of Bias table? Also the NNT(B) should be listed alongside the duration of follow-up in this trial (as NNT is time dependent) please.&lt;/p&gt;&lt;p&gt;Chris&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~&lt;/p&gt;&lt;p&gt;CJC Editing Feb 2007&lt;br&gt;This review has been published on the module but I have made a few grammatical changes so please use this version for updates.&lt;br&gt;Could you also document how many of the controls has Strep pneumonia in sputum isolates from the non-randomised study when you update this. What about other serotypes?&lt;br&gt;Thanks for your work on this review.&lt;br&gt;Chris&lt;br&gt;=================================&lt;br&gt;CJC Editing Oct 2006&lt;br&gt;I have taken out the Jadad scale as it will not add anything to your measures of quality in different domains. The latter fits better with the proposed bias protection which will be in RevMan 5. Risk ratio changed to Odds ratio in statistics section and GIV can be used to combine both arms of cross-overs but in this review cross-over studies are not appropriate anyway (except for short term adverse events).&lt;br&gt;If you are happy with this it can now be submitted.&lt;br&gt;Chris.&lt;/p&gt;" NOTES_MODIFIED="2017-08-09 17:27:19 +0100" NOTES_MODIFIED_BY="Emma J Dennett" REVIEW_NO="PNE-BRO" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2017-08-09 17:27:19 +0100" MODIFIED_BY="Emma J Dennett">
<TITLE>Pneumococcal vaccines for children and adults with bronchiectasis</TITLE>
<CONTACT>
<PERSON ID="0CB8362682E26AA2004A583DCFB585F0" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Christina</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Chang</LAST_NAME>
<SUFFIX/>
<POSITION>PhD student</POSITION>
<EMAIL_1>christina.chang@monash.edu</EMAIL_1>
<EMAIL_2>christina.chang@med.monash.edu.au ccchang339@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Infectious Diseases</DEPARTMENT>
<ORGANISATION>The Alfred Hospital, Monash University</ORGANISATION>
<ADDRESS_1>Commercial Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Prahran</CITY>
<ZIP>3181</ZIP>
<REGION>Victoria</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 3 92071497</PHONE_1>
<PHONE_2/>
<FAX_1>+61 3 90762431</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-08-09 17:24:30 +0100" MODIFIED_BY="Emma Dennett">
<PERSON ID="0CB8362682E26AA2004A583DCFB585F0" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Christina</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Chang</LAST_NAME>
<SUFFIX/>
<POSITION>PhD student</POSITION>
<EMAIL_1>christina.chang@monash.edu</EMAIL_1>
<EMAIL_2>christina.chang@med.monash.edu.au ccchang339@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Infectious Diseases</DEPARTMENT>
<ORGANISATION>The Alfred Hospital, Monash University</ORGANISATION>
<ADDRESS_1>Commercial Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Prahran</CITY>
<ZIP>3181</ZIP>
<REGION>Victoria</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 3 92071497</PHONE_1>
<PHONE_2/>
<FAX_1>+61 3 90762431</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="EEDB3C0982E26AA2009C393DD340A170" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Rosalyn</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Singleton</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant in Immunzation and Paediatrician</POSITION>
<EMAIL_1>ris2@cdc.gov</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Arctic Investigations Program and Alaska Native Tribal Health Consortium</DEPARTMENT>
<ORGANISATION>Centers for Disease Control and Prevention, National Center for Infectious Diseases,</ORGANISATION>
<ADDRESS_1>4055 Tudor Centre Dr.</ADDRESS_1>
<ADDRESS_2/>
<CITY>Anchorage</CITY>
<ZIP>AK 99508</ZIP>
<REGION>Alaska</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>1-907 729 3418</PHONE_1>
<PHONE_2/>
<FAX_1>1-907 729 3429</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="4854" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>Morris</LAST_NAME>
<SUFFIX/>
<POSITION>Paediatrician, Royal Darwin Hospital and Deputy Head</POSITION>
<EMAIL_1>Peter.Morris@menzies.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Child Health Division</DEPARTMENT>
<ORGANISATION>Menzies School of Health Research, Charles Darwin University</ORGANISATION>
<ADDRESS_1>PO Box 41096</ADDRESS_1>
<ADDRESS_2/>
<CITY>Darwin</CITY>
<ZIP>0811</ZIP>
<REGION>Northern Territory</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 8 8922 8196 ext: 28371</PHONE_1>
<PHONE_2>+61 8 8948 2291</PHONE_2>
<FAX_1>+61 8 8922 5187</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12396" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Anne</FIRST_NAME>
<MIDDLE_INITIALS>B</MIDDLE_INITIALS>
<LAST_NAME>Chang</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Research Principal Fellow, NHMRC Practitioner Fellow</POSITION>
<EMAIL_1>Anne.Chang@menzies.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Child Health Division</DEPARTMENT>
<ORGANISATION>Menzies School of Health Research, Charles Darwin University</ORGANISATION>
<ADDRESS_1>PO Box 41096</ADDRESS_1>
<ADDRESS_2/>
<CITY>Darwin</CITY>
<ZIP>0811</ZIP>
<REGION>Northern Territories</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 411 699022</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2009-03-12 11:06:18 +0000" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;Minor update: 27/02/07&lt;/p&gt;&lt;p&gt;New studies sought but none found: 20/11/07&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 17/10/06&lt;/p&gt;" NOTES_MODIFIED="2009-03-12 11:06:18 +0000" NOTES_MODIFIED_BY="Toby Lasserson">
<UP_TO_DATE>
<DATE DAY="4" MONTH="12" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="11" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="11" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2017-08-09 17:27:19 +0100" MODIFIED_BY="Emma J Dennett">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-08-09 17:27:19 +0100" MODIFIED_BY="Emma J Dennett">
<DATE DAY="5" MONTH="7" YEAR="2017"/>
<DESCRIPTION>
<P>New literature search run to assess the need to update this review. One potentially eligible study protocol identified and added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-08-09 17:25:01 +0100" MODIFIED_BY="Emma J Dennett">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-08-09 17:25:01 +0100" MODIFIED_BY="Emma J Dennett">
<DATE DAY="5" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>PLS title amended</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-06-05 17:17:14 +0100" MODIFIED_BY="Emma J Welsh">
<DATE DAY="12" MONTH="3" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2009-03-12 11:06:41 +0000" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="4" MONTH="12" YEAR="2008"/>
<DESCRIPTION>
<P>Study on 167 people added to review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-03-12 11:06:39 +0000" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="12" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Literature search re-run</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-01-05 14:40:44 +0000" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="16" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="10" MONTH="12" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Royal Children's Hospital Foundation, Brisbane</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>National Health and Medical Research Council</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-06-05 17:18:40 +0100" MODIFIED_BY="Toby J Lasserson">
<SUMMARY MODIFIED="2014-06-05 17:18:11 +0100" MODIFIED_BY="Christopher J Cates">
<TITLE MODIFIED="2014-06-05 17:17:37 +0100" MODIFIED_BY="Toby J Lasserson">Pneumonia (pneumococcal) vaccines for children and adults with bronchiectasis</TITLE>
<SUMMARY_BODY MODIFIED="2014-06-05 17:18:11 +0100" MODIFIED_BY="Christopher J Cates">
<P>In many countries pneumonia vaccination (for the protection against infection of the bacteria pneumococcus), is part of the immunisation schedule for infants as well as for people with bronchiectasis. In this review, our search for randomised control trials that examined the effectiveness of pneumococcal vaccines for people with bronchiectasis revealed one randomised and one quasi-controlled trial. We conclude that, albeit the limitations of the review, adults and children (when age appropriate) with bronchiectasis should be vaccinated with the 23-valent polysaccharide pneumococcal vaccine as suggested in many national guidelines. Due to absence of data on how often the vaccine should be given, we recommend that national guidelines be followed until further evidence is available.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-01-12 10:23:14 +0000" MODIFIED_BY="Christopher J Cates">
<ABS_BACKGROUND>
<P>Bronchiectasis is increasingly recognized as a major cause of respiratory morbidity especially in developing countries. Even in affluent countries, bronchiectasis is increasingly seen in some community subsections (e.g. Aboriginal communities) and occurs as a comorbidity and disease modifier in respiratory diseases such as chronic obstructive pulmonary disease (COPD). Respiratory exacerbations in people with bronchiectasis are associated with reduced quality of life, accelerated pulmonary decline, hospitalisation and even death. Conjugate pneumococcal vaccine is part of the routine infant immunisation schedule in many countries. Current recommendations for additional pneumococcal vaccination include children and adults with chronic suppurative disease. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the effectiveness of pneumococcal vaccine as routine management in children and adults with bronchiectasis in (a) reducing the severity and frequency of respiratory exacerbations and (b) pulmonary decline.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates">
<P>The Cochrane Register of Controlled Trials (CENTRAL), the Cochrane Airways Group Specialised Register, MEDLINE and EMBASE databases were searched by the Cochrane Airways Group. Pharmaceutical manufacturers of pneumococcal vaccines were also contacted. The latest searches were performed in November 2008.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised controlled trials that utilised pneumococcal vaccine on children and adults with bronchiectasis. All types of pneumococcal vaccines were included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Results of searches were reviewed against pre-determined criteria for inclusion. No eligible trials were identified and thus no data was available for analysis. One small non-randomised controlled trial in children was reported. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-01-12 10:23:14 +0000" MODIFIED_BY="Christopher J Cates">
<P>One randomised controlled open label study in 167 adults with chronic lung disease (bronchiectasis and other diseases associated with bronchiectasis) compared 23-valent pneumococcal (PV) and influenza vaccine with influenza vaccine alone (control group). The study found a significant reduction in acute infective respiratory exacerbations in the PV group compared to the control group, OR=0.48 (95%CI 0.26, 0.88); number needed to treat to benefit = 6 (95%CI 4, 32) over 2-years. There was however no difference in episodes of pneumonia between groups and no data on pulmonary decline was available. In another study, a benefit in elimination of Strep. pneumoniae in the sputum was found in a non-randomised trial in children but no clinical effect was described.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates">
<P>Current but limited evidence support the use of 23-valent pneumococcal vaccine as routine management in adults with bronchiectasis. Circumstantial evidence also support the use of routine 23-valent pneumococcal vaccination in children with bronchiectasis. Further randomised controlled trials examining the efficacy of this intervention using various vaccine types in different age groups are needed. There is no data on the efficacy of pneumococcal vaccine on pulmonary decline. With the lack of evidence in how often the vaccine should be given, it is recommended that health providers adhere to national guidelines. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-06-05 17:18:40 +0100" MODIFIED_BY="Toby J Lasserson">
<BACKGROUND MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates">
<P>Bronchiectasis, sometimes termed an 'orphan's disease' (<LINK REF="REF-Callahan-2002" TYPE="REFERENCE">Callahan 2002</LINK>) is increasingly recognized as a major cause of respiratory morbidity especially in developing countries (<LINK REF="REF-Karadag-2005" TYPE="REFERENCE">Karadag 2005</LINK>) and in pockets of affluent countries (<LINK REF="REF-Chang-2003" TYPE="REFERENCE">Chang 2003</LINK>, <LINK REF="REF-Singleton-2000" TYPE="REFERENCE">Singleton 2000</LINK>). Of diverse aetiology, bronchiectasis is often a result of repeated respiratory infections or may be due to rare immune deficiencies. Increasingly recognised as a common final pathway for a variety of diseases, it is seen to complicate both common and uncommon respiratory illnesses such as COPD, bronchiolitis obliterans, pan bronchiolitis (<LINK REF="REF-Poletti-2006" TYPE="REFERENCE">Poletti 2006</LINK>), pneumoconiosis (<LINK REF="REF-Altin-2004" TYPE="REFERENCE">Altin 2004</LINK>), interstitial lung disease and sarcoidosis (<LINK REF="REF-Patel-2004" TYPE="REFERENCE">Patel 2004</LINK>, <LINK REF="REF-Chang-1998" TYPE="REFERENCE">Chang 1998</LINK>, <LINK REF="REF-Lewis-2002" TYPE="REFERENCE">Lewis 2002</LINK>) and also secondary pulmonary illnesses such as autoimmune diseases and post tuberculosis (TB) (<LINK REF="REF-Buckles-1951" TYPE="REFERENCE">Buckles 1951</LINK>). Its coexistence increases the morbidity and mortality of the underlying disease (<LINK REF="REF-Patel-2004" TYPE="REFERENCE">Patel 2004</LINK>, <LINK REF="REF-Lewis-2002" TYPE="REFERENCE">Lewis 2002</LINK>, <LINK REF="REF-Keistinen-1997" TYPE="REFERENCE">Keistinen 1997</LINK>). For instance, bronchiectasis is reported to occur in 29-50% of COPD (<LINK REF="REF-Patel-2004" TYPE="REFERENCE">Patel 2004</LINK>, <LINK REF="REF-O_x0027_Brien-2000" TYPE="REFERENCE">O'Brien 2000</LINK>) and when present, increases the severity and frequency of respiratory exacerbations (<LINK REF="REF-Patel-2004" TYPE="REFERENCE">Patel 2004</LINK>, <LINK REF="REF-Gursel-2006" TYPE="REFERENCE">Gursel 2006</LINK>). Thus, management of the symptoms and prevention of progression of bronchiectasis is important.</P>
<P>The dominant symptoms and signs of bronchiectasis are a productive or wet cough, dyspnoea on exertion and presence of other respiratory signs (clubbing, chest wall deformity, respiratory noises such as wheeze or crepitations on auscultation). In the long term, pulmonary decline may occur (<LINK REF="REF-Keistinen-1997" TYPE="REFERENCE">Keistinen 1997</LINK>, <LINK REF="REF-Twiss-2006" TYPE="REFERENCE">Twiss 2006</LINK>). Children and adults with bronchiectasis suffer from recurrent acute exacerbations, some necessitating inpatient care. Effective management regimes for bronchiectasis should improve quality of life, reduce the frequency and severity of respiratory exacerbations and rate of pulmonary decline. Cole's 'vicious circle hypothesis' suggests microbial colonization or infection as a key factor in its pathophysiology as this often leads to bronchial obstruction and a normal or exaggerated inflammatory response (<LINK REF="REF-Cole-1986" TYPE="REFERENCE">Cole 1986</LINK>). Treatment modalities that prevent or limit respiratory infections should thus, prevent or reduce respiratory decline. Respiratory infection alone increases morbidity and reduces the quality of life in those with bronchiectasis (<LINK REF="REF-Martinez_x002d_Garcia-2005" TYPE="REFERENCE">Martinez-Garcia 2005</LINK>). Pneumococcal respiratory infections is a common respiratory pathogen in acute (<LINK REF="REF-Lucero-2004" TYPE="REFERENCE">Lucero 2004</LINK>) and chronic respiratory diseases (<LINK REF="REF-Devitt--1977" TYPE="REFERENCE">Devitt 1977</LINK>). Prevention of pneumococcal infections through the use of pneumococcal vaccine should in turn, be a useful routine management modality for children and adults with bronchiectasis. Indeed 5-yearly pneumococcal vaccination is recommended for patients with bronchiectasis (<LINK REF="REF-Chang-2002" TYPE="REFERENCE">Chang 2002</LINK>).</P>
<P>Pneumococcal vaccines are available in two major types; the older pneumococcal polysaccharide vaccine and the more recent pneumococcal conjugate vaccine. The 23-valent polysaccharide vaccine (PPV23) contains polysaccharide antigen from 23 serotypes and vaccine efficacy against invasive disease is estimated at 38-53% (<LINK REF="REF-Conaty--2004" TYPE="REFERENCE">Conaty 2004</LINK>). Although clinical trials in younger adults have generally shown efficacy against pneumococcal pneumonia and, or bacteraemia, the trial evidence in the elderly is less robust (<LINK REF="REF-Honkanen-1999" TYPE="REFERENCE">Honkanen 1999</LINK>). Effectiveness in case-control studies generally range from 56-81% except Forrester et al who demonstrated no effectiveness (<LINK REF="REF-Forrester-1987" TYPE="REFERENCE">Forrester 1987</LINK>). The PPV23 vaccine is relatively ineffective in young children aged under 2 years (<LINK REF="REF-Lee-2003" TYPE="REFERENCE">Lee 2003</LINK>). The heptavalent pneumococcal conjugated vaccine (PCV7) is directed against seven serotypes and recommended for use in children less than 5 years of age (<LINK REF="REF-McEllistrem-2005" TYPE="REFERENCE">McEllistrem 2005</LINK>). Universal childhood vaccination in the United States has resulted in 70% decrease in invasive pneumococcal disease (IPD) in children &lt;2 years and indirectly, contributed to prevention of adult IPD (<LINK REF="REF-Lexau-2005" TYPE="REFERENCE">Lexau 2005</LINK>). The possibility of replacement serotype disease mandates continued data surveillance (<LINK REF="REF-McEllistrem-2005" TYPE="REFERENCE">McEllistrem 2005</LINK>). Vaccines also incur cost and can result in adverse reactions, mostly occurring as local pain and swelling (<LINK REF="REF-Walker-2005" TYPE="REFERENCE">Walker 2005</LINK>, <LINK REF="REF-Jackson-2006" TYPE="REFERENCE">Jackson 2006</LINK>). A review on the efficacy of pneumococcal vaccines for bronchiectasis will help guide clinical practice.</P>
<P>Efficacy of pneumococcal vaccines for other chronic respiratory diseases (<LINK REF="REF-Sheikh-2002" TYPE="REFERENCE">Sheikh 2002</LINK>, <LINK REF="REF-Granger-2006" TYPE="REFERENCE">Granger 2006</LINK>) and otitis media (<LINK REF="REF-Straetemans-2004" TYPE="REFERENCE">Straetemans 2004</LINK>) are covered in other Cochrane reviews. This systematic review will evaluate the evidence of efficacy of pneumococcal vaccination in children and adults with bronchiectasis.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the effectiveness of pneumococcal vaccine as routine management in children and adults with bronchiectasis in (a) reducing the severity and frequency of respiratory exacerbations and (b) pulmonary decline.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-06-05 17:18:39 +0100" MODIFIED_BY="Christopher J Cates">
<SELECTION_CRITERIA MODIFIED="2014-06-05 17:18:39 +0100" MODIFIED_BY="Emma J Welsh">
<CRIT_STUDIES>
<P>All randomised controlled trials using pneumococcal vaccine in patients with bronchiectasis.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adults or children with bronchiectasis (defined clinically or radiologically).<BR/>Exclusion criteria: Participants with other diseases where bronchiectasis is not present.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>All randomised controlled trials that utilised pneumococcal vaccine on children and adults with bronchiectasis. All types of pneumococcal vaccines were included.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-06-05 17:18:39 +0100" MODIFIED_BY="Emma J Welsh">
<P>Attempts were made to obtain data on at least one of the following outcome measures:</P>
<P>(A) for short term effectiveness (12 months or less)<BR/>a) proportions of participants who had respiratory exacerbations<BR/>b) proportions of participants who were hospitalised,<BR/>c) total numbers of days with respiratory symptoms<BR/>d) total number of hospitalised days<BR/>e) mean difference in bronchiectasis severity control (QOL, cough diary, Likert scale, visual analogue scale, level of interference of cough, cough diary, etc),<BR/>f) proportions experiencing adverse effects of the intervention, (e.g. local reaction, exacerbation immediately post vaccination, systemic effects (myalgia, fever, fatigue), etc)<BR/>Outcomes (a) to (e) will be examined globally as well as also specifically to proven pneumococcal infections (from airway specimens or rising titres)</P>
<P>(B) for medium to long term outcomes (more than 1 year)<BR/>g) radiology scores (high resolution computed tomography scans or chest radiograph)<BR/>h) lung function<BR/>I) bronchiectasis severity control (QOL, cough diary, Likert scale, visual analogue scale, level of interference of cough, cough diary, etc),<BR/>j) relevant airway markers of inflammation.<BR/>k) other non-respiratory outcomes (otitis media, bacteraemia, meningitis, etc) caused by pneumococcus.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates">
<P>The following topic search strategy was used to identify relevant randomised controlled trials from electronic databases:<BR/>
<BR/>("bronchiectasis" OR "suppurative lung disease") AND ((vaccin* OR immunis*) AND (pneum*)) (all as textword or index terms). For the full strategies see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>Trials were identified from the following sources:<BR/>1. The Cochrane Airways Group Specialised Trials Register<BR/>2. The Cochrane Central Register of Controlled Trials (CENTRAL)<BR/>3. MEDLINE (1966 to Nov 2008). Topic search strategy combined with the RCT search filter as outlined in the Airways Group module.<BR/>4. OLDMEDLINE (1950 to 1965). Topic search strategy combined with the RCT search filter as outlined in the Airways Group module.<BR/>5. EMBASE (1980 to Nov 2008).Topic search strategy combined with the RCT search filter as outlined in the Airways Group module.<BR/>6. The list of references in relevant publications.<BR/>7. Written communication with the authors of trials would have been included in the review if necessary.<BR/>7. Pharmaceutical companies that manufacture pneumococcal vaccines.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates">
<P>Retrieval of studies: From the title, abstract, or descriptors, two reviewers (CC, AC) independently reviewed literature searches to identify potentially relevant trials for full review. Searches of bibliographies and texts were conducted to identify additional studies. From the full text using specific criteria, the same two reviewers independently selected trials for inclusion. Agreement would have been measured using kappa statistics. Disagreement would have been resolved by adjudication (RS and PM).</P>
<P>It was planned that trials that satisfied the inclusion criteria would have been reviewed and the following information recorded: study setting, year of study, source of funding, patient recruitment details (including number of eligible subjects), inclusion and exclusion criteria, other symptoms, randomisation and allocation concealment method, numbers of participants randomised, blinding (masking) of participants, care providers and outcome assessors, dose and type of intervention, duration of therapy, co-interventions, numbers of patients not followed up, reasons for withdrawals from study protocol (clinical, side-effects, refusal and other), details on side-effects of therapy, and whether intention-to-treat analyses were possible. Data would have been extracted on the outcomes described previously. Further information would have been requested from the authors when required.</P>
<P>The Revman 5 'risk of bias tool' as outlined in the Cochrane handbook (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) was utilised. </P>
<P>STATISTICS<BR/> Results from studies that met the inclusion criteria and reported any of the outcomes of interest were included in the meta-analyses when possible. For continuous variables, the summary weighted odds ratio and 95% confidence interval (fixed effects model) would have been calculated (Cochrane statistical package, RevMan version 5). Studies using cross-over designs would be of limited value and it was planned that only the first arm of the cross-study (if any) would be utilised. Numbers needed to treat for benefit (NNTB) was calculated from the pooled OR and its 95% CI applied to a specified baseline risk using an online calculator (<LINK REF="REF-Cates-2003" TYPE="REFERENCE">Cates 2003</LINK>). If studies reported outcomes using different measurement scales, the standardised mean difference would have been estimated. Any heterogeneity between the study results would have been described and tested to see if it reached statistical significance using a chi-squared test. The 95% confidence interval estimated using a random effects model would have been included whenever there are concerns about statistical heterogeneity.</P>
<P>SUB-GROUP ANALYSIS:<BR/>The following a priori sub-group analyses was planned:<BR/>1. children (aged 18 years or less) and adults (&gt;18 years)<BR/>2. types of pneumococcal vaccine<BR/>3. type of control group<BR/>4. participant type (bronchiectasis as primary disease vs bronchiectasis as co-existent disease)<BR/>5. severity of bronchiectasis (based on lung function)</P>
<P>Sensitivity analyses were also planned to assess the impact of the potentially important factors on the overall outcomes:<BR/>a) study quality;<BR/>b) variation in the inclusion criteria;<BR/>c) differences in the medications used in the intervention and comparison groups;<BR/>d) differences in outcome measures;<BR/>e) analysis using random effects model;<BR/>f) analysis by "treatment received"; and<BR/>g) analysis by "intention-to-treat".</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-06-05 17:18:40 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_DESCRIPTION MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates">
<P>In the original search (2006) the Airways Group specialised register/search identified 44 potentially relevant titles. After assessing the abstracts, 3 publications were considered for inclusion into review including one non-English article (Russian). Of the 3 potentially relevant publication but none fulfilled the study eligibility criteria (see Table of excluded studies). No additional studies were found in the review articles. No additional data were available from the two pharmaceutical companies contacted (Merck Sharp &amp; Dohme and Wyeth in Australia). The 2007 search revealed 5 abstracts of which none fulfilled the inclusion criteria. The 2008 search revealed 8 papers and one study (<LINK REF="STD-Furumoto-2008" TYPE="STUDY">Furumoto 2008</LINK>) was included. </P>
<P>The included study has been described in the Characteristics of included studies table. Some subjects had very severe lung disease (59 on home oxygen, 11 on home ventilation). The study was included as some subjects were clearly described as having bronchiectasis. The respiratory condition the other subjects had, has a large overlap with bronchiectasis especially when the disease is severe. Subjects were followed up for 2 years. There were no randomised controlled studies in children that assessed clinical outcomes. There was one quasi controlled study (<LINK REF="STD-Ryzhov-2005" TYPE="STUDY">Ryzhov 2005</LINK>) that utilised a comparative group published in Russian (<LINK REF="STD-Ryzhov-2005" TYPE="STUDY">Ryzhov 2005</LINK>). In this study (<LINK REF="STD-Ryzhov-2005" TYPE="STUDY">Ryzhov 2005</LINK>) in children with chronic lung disease (including bronchiectasis), 25 were vaccinated with PPV23, 13 with Haemophilus influenzae vaccine and 40 children were not vaccinated. As there was otherwise little data, this study could not be included in the meta-analysis.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates">
<P>Please see risk of bias table in i<LINK TAG="INCLUDED_STUDIES" TYPE="SECTION">ncluded studies</LINK> section. The sole randomised study (<LINK REF="STD-Furumoto-2008" TYPE="STUDY">Furumoto 2008</LINK>) included in this review has high risk of performance and detection bias. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-06-05 17:18:40 +0100" MODIFIED_BY="Toby J Lasserson">
<P>
<U>
<B>Adults</B>
</U>
</P>
<P>
<U>Effect on exacerbations (</U>
<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>
<U>):</U>
</P>
<P>For number of people having had any respiratory exacerbations, the PV23 group was significantly better (less subjects with exacerbations) then the control group, OR 0.53 (95%CI 0.29, 0.99) <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, NNTB over 2-years was 7 (95%CI 4, 424). With further evaluation, the difference between groups was mainly related to infective exacerbations (i.e. respiratory symptoms with increase in blood white cell count or serum C-reactive protein, as described in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Comparing the PV23 group to controls, the OR for infective exacerbations was OR=0.48 (95%CI 0.26, 0.88); number needed to treat to benefit=6 (95%CI 4, 32) over 2-years, see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>. That for non-infective exacerbations was non significant, OR 1.42 (0.48, 4.19).</P>
<P>
<U>Effect on pneumonia (</U>
<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>): There was no difference between groups for the outcome of pneumonia</P>
<P>
<U>Other outcomes: </U>
<LINK REF="STD-Furumoto-2008" TYPE="STUDY">Furumoto 2008</LINK> did not report on any pulmonary function. Seven subjects in each group (8.4% of the cohort studied) died during the follow up period of the study.</P>
<P>
<U>
<B>Children</B>
</U>
</P>
<P>There was only one study in children with bronchiectasis and this study utilised a comparative group, (i.e. a non-randomised study) published in Russian (<LINK REF="STD-Ryzhov-2005" TYPE="STUDY">Ryzhov 2005</LINK>). In this study (<LINK REF="STD-Ryzhov-2005" TYPE="STUDY">Ryzhov 2005</LINK>) in children with chronic lung disease (including bronchiectasis), 25 were vaccinated with PPV23, 13 with Haemophilus influenzae vaccine and 40 children were not vaccinated. The authors described that, a year after vaccination with PPV23, <I>S. pneumoniae</I> were isolated in monoculture in 3 out of 25 cases (88% elimination) (<LINK REF="STD-Ryzhov-2005" TYPE="STUDY">Ryzhov 2005</LINK>).</P>
<P>It was not possible to perform any relevant sub-analysis.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-01-12 10:23:14 +0000" MODIFIED_BY="Christopher J Cates">
<P>In this review that evaluated the efficacy of pneumococcal vaccine in people with bronchiectasis for pulmonary outcomes, we found only one randomised controlled trial that was subject to bias as it was an open-labelled trial. Nevertheless the study in 167 adults with chronic lung disease found that PV23 vaccination significantly reduced the number of people with respiratory exacerbation with NNTB of 7 (95%CI 4, 424) over 2-years. The majority of this effect related to infective exacerbations, NNTB 6 (95%CI 4, 32) over 2-years. There was no difference between groups on number with pneumonia and no data for pulmonary decline was found. One controlled study that was not randomised (Ryzhov 2005) described efficacy with respect to microbiology of the sputum (88% elimination of S pneumoniae) but clinical evaluation was not examined in children.</P>
<P>Large trials and meta-analysis have demonstrated that pneumococcal vaccination protects children and adults from invasive pneumococcal disease (<LINK REF="REF-de-Roux-2005" TYPE="REFERENCE">de Roux 2005</LINK>), thus many recommendations exist for regular pneumococcal vaccination for those at risk (including patients with suppurative lung disease). This Cochrane review has significant limitations with the lack of studies. . Whilst we cannot always "wait for perfect data", others have cautioned against "availability creep" with respect to the gap between policy and evidence (<LINK REF="REF-Jefferson-2006" TYPE="REFERENCE">Jefferson 2006</LINK>). Until additional RCTs are undertaken to examine the question, we cannot be absolutely confident with the findings of this review that routine pneumococcal vaccination in children and adults with bronchiectasis is beneficial. The feasibility of performing RCTs in this target group is in question. For now, as children and adults with bronchiectasis are at increased risk for pneumonia and pneumococcal disease and there is some evidence that pneumococcal vaccine can reduce pneumonia and invasive pneumococcal disease (<LINK REF="REF-Lucero-2004" TYPE="REFERENCE">Lucero 2004</LINK>), it would be prudent that providers follow guidelines from the national bodies such as Advisory Committee on Immunization Practices (in USA) (<LINK REF="REF-ACIP" TYPE="REFERENCE">ACIP</LINK>) and NIPS (Australia) (<LINK REF="REF-NIPS" TYPE="REFERENCE">NIPS</LINK>) regarding recommendations for pneumococcal vaccination of persons with bronchiectasis.</P>
<P>It is debatable whether the study (Furumoto 2008) we have included in this review fulfilled all the inclusion criteria, specifically that related to the diagnosis. We decided to include the study because a subgroup definitely had bronchiectasis and all the lung conditions in the subjects have a large overlap with bronchiectasis especially when the disease is severe. Although the study did not describe the severity of the chronic lung disease in all the subjects, it is likely that they were in the severe spectrum (35.3% of cohort was on ambulatory oxygen and 6.6% was on home ventilation). Unless a HRCT scan is performed on each subject, it is very difficult to ascertain whether radiological bronchiectasis is present. The study was also limited with a risk of performance and detection bias. Nevertheless, in infective exacerbations where the greatest significance between groups was found, objective blood tests were utilised.</P>
<P>There was no data on how frequent pneumococcal vaccine should be given after the initial vaccination. Some advocate repeating PV23 after 5 years. In the absence of data on frequency of vaccination, we advocate that national guidelines be adhered to.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates">
<IMPLICATIONS_PRACTICE MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates">
<P>Limited evidence support the routine use of polysaccharide 23-valent pneumococcal vaccine in adults with chronic lung disease including those with bronchiectasis. Other circumstantial data also suggests that pneumococcal vaccination is beneficial in children. There is no data on the efficacy of pneumococcal vaccine on pulmonary decline. There is also no data on how often the vaccination should be repeated. With the lack of evidence on this, it is recommended that health providers adhere to national guidelines. Individual risk factors for adverse events should be taken into account.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates">
<P>Randomised controlled trials to establish the efficacy of pneumococcal vaccination in reducing severity and frequency of respiratory exacerbations and pulmonary decline in people with bronchiectasis are needed. As vaccine response alters with age, age-based cohorts should include young children (less than 2 years), children, adults and older adults. Various vaccine types and microbiological surveillance for possible serotype replacement should also be examined in these RCTs. However the difficulty in performing a RCT in the target group is acknowledged.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates">
<P>We thank Toby Lasserson and Chris Cates from the Airways Group for their advice, supportive role and comments to the protocol and review. We are also grateful to Susan Hansen and Elizabeth Arnold for performing the relevant searches and obtaining the articles. We also thank Dr. Vasiliy Vlassov for translation of the Russian article.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None declared.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>For the protocol: Protocol was written by both CC and AC. RS reviewed the protocol. For the review: CC and AC selected articles from search, extracted data and wrote the review. RS and PM contributed to writing the review and would have been adjudicators if disagreements had occurred.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-08-21 16:35:54 +0100" MODIFIED_BY="Emma Dennett">
<STUDIES MODIFIED="2017-08-09 17:27:10 +0100" MODIFIED_BY="Emma J Dennett">
<INCLUDED_STUDIES MODIFIED="2009-01-07 15:31:26 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Furumoto-2008" MODIFIED="2009-01-07 15:31:26 +0000" MODIFIED_BY="[Empty name]" NAME="Furumoto 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-01-07 15:31:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Furumoto A, Ohkusa Y, Chen M, Kawakami K, Masaki H, Sueyasu Y, et al</AU>
<TI>Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease</TI>
<SO>Vaccine</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>33</NO>
<PG>4284-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3445111"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3445110"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Ryzhov-2005" NAME="Ryzhov 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ryzhov AA, Katosova LK, Kostinov MP, Volkov IK, Magarshak OO</AU>
<TI>Evaluation of the influence of the bacterial vaccines Pneumo-23 and Act-HIB on the course of the chronic inflammatory process of the respiratory organs in children</TI>
<SO>Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>3</NO>
<PG>84-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3445113"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3445112"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Kessel-2005" NAME="van Kessel 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Kessel DA, van Velzen-Blad H, van den Bosch JM, Rijkers GT</AU>
<TI>Impaired pneumococcal antibody response in bronchiectasis of unknown aetiology</TI>
<SO>European Respiratory Journal</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>3</NO>
<PG>482-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3445115"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3445114"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vendrell-2005" NAME="Vendrell 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vendrell M, De Gracia J, Rodrigo MJ, Cruz MJ, Alvarez A, Garcia M, et al</AU>
<TI>Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology</TI>
<SO>Chest</SO>
<YR>2005</YR>
<VL>127</VL>
<NO>1</NO>
<PG>197-204</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3445117"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3445116"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2017-08-09 17:27:10 +0100" MODIFIED_BY="Emma J Dennett">
<STUDY DATA_SOURCE="PUB" ID="STD-O-Grady-2015" MODIFIED="2017-08-09 17:27:10 +0100" MODIFIED_BY="Emma J Dennett" NAME="O Grady 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-08-09 17:27:07 +0100" MODIFIED_BY="Emma J Dennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Grady KA, Grimwood K, Cripps A, Mulholland EK, Morris P, Torzillo PJ et al</AU>
<TI>Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial</TI>
<SO>Trials</SO>
<YR>2013</YR>
<VL>14</VL>
<NO>1</NO>
<PG>282</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6614827"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6614826"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates">
<ADDITIONAL_REFERENCES MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates">
<REFERENCE ID="REF-ACIP" MODIFIED="2009-01-07 15:31:45 +0000" MODIFIED_BY="[Empty name]" NAME="ACIP" TYPE="OTHER">
<AU>ACIP</AU>
<TI>Advisory Committee on Immunization Practices</TI>
<SO>http://www.cdc.gov/nip/menus/vaccines.htm</SO>
<YR>(accessed Dec 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altin-2004" MODIFIED="2009-01-07 15:32:05 +0000" MODIFIED_BY="[Empty name]" NAME="Altin 2004" TYPE="JOURNAL_ARTICLE">
<AU>Altin R, Savranlar A, Kart L, Mahmutyazicioglu K, Ozdemir H, Akdag B, et al</AU>
<TI>Presence and HRCT quantification of bronchiectasis in coal workers</TI>
<SO>European Journal of Radiology</SO>
<YR>2004</YR>
<VL>52</VL>
<NO>2</NO>
<PG>157-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buckles-1951" MODIFIED="2009-01-07 15:33:03 +0000" MODIFIED_BY="[Empty name]" NAME="Buckles 1951" TYPE="JOURNAL_ARTICLE">
<AU>Buckles MG, Potts WL, Davidson HB, Neptune WB</AU>
<TI>Bronchography in pulmonary tuberculosis, with histopathologic correlation in 82 resections</TI>
<SO>American Review of Tuberculosis</SO>
<YR>1951</YR>
<VL>64</VL>
<NO>4</NO>
<PG>394-407</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Callahan-2002" NAME="Callahan 2002" TYPE="JOURNAL_ARTICLE">
<AU>Callahan CW, Redding GJ</AU>
<TI>Bronchiectasis in children: orphan disease or persistent problem?</TI>
<SO>Pediatric pulmonology</SO>
<YR>2002</YR>
<VL>33</VL>
<NO>6</NO>
<PG>492-496</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cates-2003" NAME="Cates 2003" TYPE="COCHRANE_REVIEW">
<AU>Cates CJ, Jefferson TO, Bara AI, Rowe BH</AU>
<TI>Vaccines for preventing influenza in people with asthma (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD000364. DOI: 10.1002/14651858.CD000364.pub2."/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chang-1998" NAME="Chang 1998" TYPE="JOURNAL_ARTICLE">
<AU>Chang AB, Masel JP, Masters B</AU>
<TI>Post-infectious bronchiolitis obliterans: clinical, radiological and pulmonary function sequelae</TI>
<SO>Pediatric Radiology</SO>
<YR>1998</YR>
<VL>28</VL>
<NO>1</NO>
<PG>23-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-2002" NAME="Chang 2002" TYPE="JOURNAL_ARTICLE">
<AU>Chang AB, Grimwood K, Mulholland EK, Torzillo PJ</AU>
<TI>Bronchiectasis in Indigenous children in remote Australian communities</TI>
<SO>Medical Journal of Australia</SO>
<YR>2002</YR>
<VL>177</VL>
<NO>4</NO>
<PG>200-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-2003" MODIFIED="2009-01-07 15:33:52 +0000" MODIFIED_BY="[Empty name]" NAME="Chang 2003" TYPE="JOURNAL_ARTICLE">
<AU>Chang AB, Masel JP, Boyce NC, Wheaton G, Torzillo PJ</AU>
<TI>Non-CF bronchiectasis-clinical and HRCT evaluation</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2003</YR>
<VL>35</VL>
<PG>477-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cole-1986" NAME="Cole 1986" TYPE="JOURNAL_ARTICLE">
<AU>Cole PJ</AU>
<TI>Inflammation: a two edged sword. The model of bronchiectasis</TI>
<SO>European Journal Respiratory Disease</SO>
<YR>1986</YR>
<VL>147</VL>
<NO>Suppl</NO>
<PG>6-15</PG>
<EN>147</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conaty--2004" NAME="Conaty  2004" TYPE="JOURNAL_ARTICLE">
<AU>Conaty S, Watson L, Dinnes J, Waugh N</AU>
<TI>The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials</TI>
<SO>Vaccine</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>23-24</NO>
<PG>3214-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Roux-2005" NAME="de Roux 2005" TYPE="JOURNAL_ARTICLE">
<AU>de Roux A, Lode H</AU>
<TI>Pneumococcal vaccination</TI>
<SO>European Respiratory Journal</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>6</NO>
<PG>982-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Devitt--1977" NAME="Devitt  1977" TYPE="JOURNAL_ARTICLE">
<AU>Devitt L, Riley I, Hansman D</AU>
<TI>Human infection caused by penicillin-insensitive pneumococci</TI>
<SO>Medical Journal of Australia</SO>
<YR>1977</YR>
<VL>1</VL>
<NO>16</NO>
<PG>586-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Forrester-1987" MODIFIED="2009-01-07 15:34:12 +0000" MODIFIED_BY="[Empty name]" NAME="Forrester 1987" TYPE="JOURNAL_ARTICLE">
<AU>Forrester HL, Jahnigen DW, LaForce FM</AU>
<TI>Inefficacy of pneumococcal vaccine in a high-risk population</TI>
<SO>American Journal of Medicine</SO>
<YR>1987</YR>
<VL>83</VL>
<NO>3</NO>
<PG>425-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Granger-2006" NAME="Granger 2006" TYPE="COCHRANE_REVIEW">
<AU>Granger R, Walters J, Poole PJ, Lasserson TJ, Mangtani P, Cates CJ et al</AU>
<TI>Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD001390. DOI: 10.1002/14651858.CD001390.pub2."/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gursel-2006" NAME="Gursel 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gursel G</AU>
<TI>Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease?</TI>
<SO>Heart Lung</SO>
<YR>2006</YR>
<VL>35</VL>
<NO>1</NO>
<PG>58-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]</TI>
<SO>The Cochrane Collaboration</SO>
<YR>2008</YR>
<PB>Available from www.cochrane-handbook.org</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Honkanen-1999" NAME="Honkanen 1999" TYPE="JOURNAL_ARTICLE">
<AU>Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E et al</AU>
<TI>Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older</TI>
<SO>Vaccine</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>20-21</NO>
<PG>2493-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jackson-2006" NAME="Jackson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jackson LA, Nelson JC, Whitney CG, Neuzil KM, Benson P, Malais D et al</AU>
<TI>Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the Vaccine Safety Datalink population</TI>
<SO>Vaccine</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>2</NO>
<PG>151-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jefferson-2006" NAME="Jefferson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jefferson T</AU>
<TI>Influenza vaccination: policy versus evidence</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>333</VL>
<NO>7574</NO>
<PG>912-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karadag-2005" NAME="Karadag 2005" TYPE="JOURNAL_ARTICLE">
<AU>Karadag B, Karakoc F, Ersu R, Kut A, Bakac S, Dagli E</AU>
<TI>Non-cystic-fibrosis bronchiectasis in children: a persisting problem in developing countries</TI>
<SO>Respiration</SO>
<YR>2005</YR>
<VL>72</VL>
<NO>3</NO>
<PG>233-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keistinen-1997" NAME="Keistinen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Keistinen T, Saynajakangas O, Tuuponen T, Kivela SL</AU>
<TI>Bronchiectasis: an orphan disease with a poorly-understood prognosis</TI>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>12</NO>
<PG>2784-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2003" NAME="Lee 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lee CJ, Lee LH, Frasch CE</AU>
<TI>Protective immunity of pneumococcal glycoconjugates</TI>
<SO>Critical Reviews in Microbiology</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>4</NO>
<PG>333-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lewis-2002" NAME="Lewis 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lewis MM, Mortelliti MP, Yeager H, Jr., Tsou E</AU>
<TI>Clinical bronchiectasis complicating pulmonary sarcoidosis: case series of seven patients</TI>
<SO>Sarcoidosis, vasculitis, and diffuse lung diseases</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>2</NO>
<PG>154-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lexau-2005" NAME="Lexau 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM et al</AU>
<TI>Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>294</VL>
<NO>16</NO>
<PG>2043-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lucero-2004" NAME="Lucero 2004" TYPE="COCHRANE_REVIEW">
<AU>Lucero MG, Dulalia VE, Parreno RN, Lim-Quianzon DM, Nohynek H, Makela H et al</AU>
<TI>Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD004977. DOI: 10.1002/14651858.CD004977."/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Martinez_x002d_Garcia-2005" NAME="Martinez-Garcia 2005" TYPE="JOURNAL_ARTICLE">
<AU>Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, Soler-Cataluna JJ</AU>
<TI>Quality-of-life determinants in patients with clinically stable bronchiectasis</TI>
<SO>Chest</SO>
<YR>2005</YR>
<VL>128</VL>
<NO>2</NO>
<PG>739-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McEllistrem-2005" NAME="McEllistrem 2005" TYPE="JOURNAL_ARTICLE">
<AU>McEllistrem MC, Adams JM, Patel K, Mendelsohn AB, Kaplan SL, Bradley JS, et al</AU>
<TI>Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>12</NO>
<PG>1738-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIPS" NAME="NIPS" TYPE="OTHER">
<TI>National Immunisation Program</TI>
<SO>http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/nips</SO>
<YR>accessed Dec 2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Brien-2000" NAME="O'Brien 2000" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien C, Guest PJ, Hill SL, Stockley RA</AU>
<TI>Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care</TI>
<SO>Thorax</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>8</NO>
<PG>635-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Patel-2004" NAME="Patel 2004" TYPE="JOURNAL_ARTICLE">
<AU>Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, et al</AU>
<TI>Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>2004</YR>
<VL>170</VL>
<NO>4</NO>
<PG>400-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poletti-2006" MODIFIED="2009-01-07 15:40:16 +0000" MODIFIED_BY="[Empty name]" NAME="Poletti 2006" TYPE="JOURNAL_ARTICLE">
<AU>Poletti V, Casoni G, Chilosi M, Zompatori M</AU>
<TI>Diffuse panbronchiolitis</TI>
<SO>European Respiratory Journal</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>4</NO>
<PG>862-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sheikh-2002" MODIFIED="2009-01-07 15:40:42 +0000" MODIFIED_BY="[Empty name]" NAME="Sheikh 2002" TYPE="COCHRANE_REVIEW">
<AU>Sheikh A, Alves B, Dhami S</AU>
<TI>Pneumococcal vaccine for asthma (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-01-07 15:40:42 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-01-07 15:40:42 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002165"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Singleton-2000" NAME="Singleton 2000" TYPE="JOURNAL_ARTICLE">
<AU>Singleton RJ, Morris A, Redding G, Poll J, Holck P, Martinez P et al</AU>
<TI>Bronchiectasis in Alaska Native children: causes and clinical courses</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2000</YR>
<VL>29</VL>
<NO>3</NO>
<PG>182-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Straetemans-2004" MODIFIED="2009-01-07 15:41:05 +0000" MODIFIED_BY="[Empty name]" NAME="Straetemans 2004" TYPE="COCHRANE_REVIEW">
<AU>Straetemans M, Sanders EAM, Veenhoven RH, Schilder AGM, Damoiseaux RAMJ, Zielhuis GA</AU>
<TI>Pneumococcal vaccines for preventing otitis media (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-01-07 15:41:05 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-01-07 15:41:05 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001480.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Twiss-2006" NAME="Twiss 2006" TYPE="JOURNAL_ARTICLE">
<AU>Twiss J, Stewart AW, Byrnes CA</AU>
<TI>Longitudinal pulmonary function of childhood bronchiectasis and comparison with cystic fibrosis</TI>
<SO>Thorax</SO>
<YR>2006</YR>
<VL>61</VL>
<NO>5</NO>
<PG>414-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walker-2005" NAME="Walker 2005" TYPE="JOURNAL_ARTICLE">
<AU>Walker FJ, Singleton RJ, Bulkow LR, Strikas RA, Butler JC</AU>
<TI>Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>12</NO>
<PG>1730-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-08-09 17:26:31 +0100" MODIFIED_BY="Emma J Dennett">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-01-12 12:18:09 +0000" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-01-12 12:18:09 +0000" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Furumoto-2008">
<CHAR_METHODS MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates">
<P>Multicentre parallel RCT involving 13 hospitals in the district of Kyushu and Okinawa (Japan) between November 2001 and April 2002. Subjects were seen monthly and with exacerbations, they visited a study physician. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-12 12:18:09 +0000" MODIFIED_BY="Toby J Lasserson">
<P>191 enrolled but 167 completed. All had chronic lung disease (COPD (n=55), bronchiectasis (20), sequelae of pulmonary tuberculosis (50), sarcoidosis (1), interstitial lung disease (9), diffuse pan bronchiolitis (5), pneumoconiosis (14), bronchial asthma (13)).</P>
<P>Inclusion criteria were patients with chronic lung disease who previously experienced acute exacerbations, were able to comply with a schedule of monthly clinical visits and were between 40 and 80 years of age. Exclusion criteria: Patients who were pregnant or had immunocompromised conditions (e.g. active malignant diseases, renal insufficiency in dialysis or HIV infection, hypogammaglobulinaemia, anatomical or functional asplenia and who had previously received 23-valent PV.</P>
<P>Mean age: pneumococcal vaccine (PV) with influenza vaccine (IV) group=67.8, SD 9.5 years; IV alone group=70.1 SD 7.4 years.</P>
<P>Gender: PV group=60 (69%), IV group=46 (57.5%)</P>
<P>Home O2 use: PV group=27 (31%), IV group=32 (40%)</P>
<P>Home non-invasive pressure ventilation: PV group=6 (6.9%), IV group=5 (6.3%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-04 08:53:33 +0000" MODIFIED_BY="Anne B Chang">
<P>23-valent pneumococcal vaccine (PV) and influenza vaccine (IV) compared to influenza vaccine alone. PV + IV group were separately immunized with 0.5 ml of PV and 0.5 ml of IV on separate occasions in 1month intervals, the participants in the IV group were immunized with 0.5 ml of IV alone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-12 10:23:14 +0000" MODIFIED_BY="Christopher J Cates">
<P>Pneumonia defined as either clinical symptoms (cough, sputum or fever) plus increased white blood cell counts or serum C-reactive protein, and the appearance of a new infiltration on a chest radiograph.</P>
<P>Acute respiratory exacerbation defined by presence of criteria: (1) increased dyspnoea, (2) increased sputum volume and (3) increased sputum purulence, and (4) absence of newly appeared infiltration on a chest radiograph. Acute exacerbation was diagnosed when two of the three respiratory symptoms existed or when one of these and one of additional symptoms, such as a fever without any other causes or increased cough was present.</P>
<P>Acute infective respiratory exacerbation: above plus when the laboratory examinations revealed an increase in white blood cell counts (WCC) or serum C-reactive protein (CRP), in addition to the clinical symptoms of acute exacerbation.</P>
<P>Acute non-infective respiratory exacerbation: clinical symptoms of acute exacerbation without increase in WCC or serum CRP.</P>
<P>Follow-up period was 2-years. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates">
<P>As all diseases in the inclusion list develop bronchiectasis, paper included </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Ryzhov-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non RCT. This study in Russian was a comparative study in 40 controls (unvaccinated ) and 25 children with chronic lung disease (including bronchiectasis) using Pneumovax 23. Hib vaccination was examined in another group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Kessel-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non RCT. Study examined antibody response to polysaccharide pneumococcal vaccine in 26 patients with bronchiectasis of unknown aetiology.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vendrell-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non RCT. Study examined antibody response to a pneumococcal unconjugate vaccine and an Haemophilus influenzae type b conjugate vaccine in all consecutive adult patients with bronchiectasis of unknown etiology .</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2017-08-09 17:26:31 +0100" MODIFIED_BY="Emma J Dennett" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-O-Grady-2015">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-01-12 10:23:14 +0000" MODIFIED_BY="Christopher J Cates">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-12-04 08:34:49 +0000" MODIFIED_BY="Anne B Chang" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-04 08:34:49 +0000" MODIFIED_BY="Anne B Chang" RESULT="UNKNOWN" STUDY_ID="STD-Furumoto-2008">
<DESCRIPTION>
<P>Not described </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-12-05 01:17:01 +0000" MODIFIED_BY="Anne B Chang" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-05 01:17:01 +0000" MODIFIED_BY="Anne B Chang" RESULT="YES" STUDY_ID="STD-Furumoto-2008">
<DESCRIPTION>
<P>Use of envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-12-05 01:17:03 +0000" MODIFIED_BY="Anne B Chang" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Pneumonia</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>Acute non-infective respiratory exacerbation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Acute infective respiratory exacerbation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-05 01:17:03 +0000" MODIFIED_BY="Anne B Chang" RESULT="NO" STUDY_ID="STD-Furumoto-2008">
<DESCRIPTION>
<P>Open label trial </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-12-05 01:16:54 +0000" MODIFIED_BY="Anne B Chang" RESULT="NO" STUDY_ID="STD-Furumoto-2008">
<DESCRIPTION>
<P>Open label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-12-04 08:39:42 +0000" MODIFIED_BY="Anne B Chang" RESULT="YES" STUDY_ID="STD-Furumoto-2008">
<DESCRIPTION>
<P>Defined by objective blood results; thus presumed blinded outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-01-12 10:23:14 +0000" MODIFIED_BY="Christopher J Cates" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Pneumonia</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Acute infective respiratory exacerbation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.03" NO="3">
<NAME>Acute non-infective respiratory exacerbation</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-12 10:23:14 +0000" MODIFIED_BY="Christopher J Cates" RESULT="YES" STUDY_ID="STD-Furumoto-2008">
<DESCRIPTION>
<P>Proportion of possible missing outcomes highly unlikely to have clinical relevant impact on intervention effect estimate (low numbers of drop outs and outcomes in both groups 0.096 episodes per person year)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-01-12 10:23:14 +0000" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Furumoto-2008">
<DESCRIPTION>
<P>Numbers lost and withdrawn in both groups given (7 in active arm, 17 in control arm) </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2009-01-12 10:23:14 +0000" MODIFIED_BY="Christopher J Cates" RESULT="UNKNOWN" STUDY_ID="STD-Furumoto-2008">
<DESCRIPTION>
<P>Numbers lost and withdrawn in both groups given (7 in active arm, 17 in control arm) </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-01-07 15:29:59 +0000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates">
<COMPARISON ID="CMP-001" MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates" NO="1">
<NAME>Adults</NAME>
<DICH_OUTCOME CHI2="3.1054941880047955" CI_END="0.8774143567367565" CI_START="0.3933917557336668" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5875096376252891" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="100" I2="35.59801181643971" I2_Q="35.580170258849805" ID="CMP-001.01" LOG_CI_END="-0.05679526370752622" LOG_CI_START="-0.40517474578143303" LOG_EFFECT_SIZE="-0.23098500474447964" METHOD="MH" MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates" NO="1" P_CHI2="0.2116658072750951" P_Q="0.21175685234549024" P_Z="0.009349084280760474" Q="3.104634097973154" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="261" TOTAL_2="240" WEIGHT="300.0" Z="2.5990181027478023">
<NAME>Number of people with one or more acute respiratory exacerbation</NAME>
<GROUP_LABEL_1>Pneumococcal vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pneumococcal vacc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9922628674888224" CI_START="0.2882224538817066" DF="0" EFFECT_SIZE="0.5347826086956522" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="50" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.0033732605304916336" LOG_CI_START="-0.5402721886258982" LOG_EFFECT_SIZE="-0.27182272457819495" MODIFIED="2008-12-04 13:11:26 +0000" MODIFIED_BY="Anne B Chang" NO="1" P_CHI2="1.0" P_Z="0.04718984513725102" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="80" WEIGHT="100.0" Z="1.9845923412167479">
<NAME>Any exacerbation</NAME>
<DICH_DATA CI_END="0.9922628674888224" CI_START="0.2882224538817066" EFFECT_SIZE="0.5347826086956522" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="50" LOG_CI_END="-0.0033732605304916336" LOG_CI_START="-0.5402721886258982" LOG_EFFECT_SIZE="-0.27182272457819495" MODIFIED="2008-12-04 13:11:26 +0000" MODIFIED_BY="Anne B Chang" ORDER="3" O_E="0.0" SE="0.3153770880557986" STUDY_ID="STD-Furumoto-2008" TOTAL_1="87" TOTAL_2="80" VAR="0.09946270767055496" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8845567394282421" CI_START="0.2561819520064657" DF="0" EFFECT_SIZE="0.47603305785123967" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="44" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.053274304268940864" LOG_CI_START="-0.5914514695175351" LOG_EFFECT_SIZE="-0.32236288689323805" MODIFIED="2008-12-04 13:10:06 +0000" MODIFIED_BY="Anne B Chang" NO="2" P_CHI2="1.0" P_Z="0.018874586036480193" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="80" WEIGHT="100.0" Z="2.347998722581461">
<NAME>Infective exacerbations</NAME>
<DICH_DATA CI_END="0.8845567394282421" CI_START="0.2561819520064657" EFFECT_SIZE="0.47603305785123967" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="44" LOG_CI_END="-0.053274304268940864" LOG_CI_START="-0.5914514695175351" LOG_EFFECT_SIZE="-0.32236288689323805" MODIFIED="2008-12-04 13:10:06 +0000" MODIFIED_BY="Anne B Chang" ORDER="2" O_E="0.0" SE="0.31612793088695706" STUDY_ID="STD-Furumoto-2008" TOTAL_1="87" TOTAL_2="80" VAR="0.09993686868686869" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.194061683043687" CI_START="0.4828607879520756" DF="0" EFFECT_SIZE="1.4230769230769231" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.6226348134465655" LOG_CI_START="-0.31617806125421133" LOG_EFFECT_SIZE="0.15322837609617704" MODIFIED="2008-12-04 13:12:35 +0000" MODIFIED_BY="Anne B Chang" NO="3" P_CHI2="1.0" P_Z="0.522308371122458" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="80" WEIGHT="100.00000000000001" Z="0.6397911802259536">
<NAME>Non-infective exacerbations</NAME>
<DICH_DATA CI_END="4.194061683043687" CI_START="0.4828607879520756" EFFECT_SIZE="1.4230769230769231" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6226348134465655" LOG_CI_START="-0.31617806125421133" LOG_EFFECT_SIZE="0.15322837609617704" MODIFIED="2008-12-04 13:12:35 +0000" MODIFIED_BY="Anne B Chang" ORDER="4" O_E="0.0" SE="0.5514633297979151" STUDY_ID="STD-Furumoto-2008" TOTAL_1="87" TOTAL_2="80" VAR="0.30411180411180405" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.331193040112217" CI_START="0.4251090598246285" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9954954954954955" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.3675782378210029" LOG_CI_START="-0.37149963935205876" LOG_EFFECT_SIZE="-0.0019607007655279116" METHOD="MH" MODIFIED="2009-01-08 13:50:55 +0000" MODIFIED_BY="Christopher J Cates" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.991702802338183" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="87" TOTAL_2="80" WEIGHT="99.99999999999999" Z="0.010399182558660108">
<NAME>Number of subjects with pneumonia</NAME>
<GROUP_LABEL_1>Pneumococcal vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3311930401122174" CI_START="0.42510905982462843" EFFECT_SIZE="0.9954954954954955" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.36757823782100296" LOG_CI_START="-0.3714996393520588" LOG_EFFECT_SIZE="-0.0019607007655279116" MODIFIED="2008-12-04 13:05:18 +0000" MODIFIED_BY="Anne B Chang" ORDER="1" O_E="0.0" SE="0.43413800354595194" STUDY_ID="STD-Furumoto-2008" TOTAL_1="87" TOTAL_2="80" VAR="0.18847580612286496" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-01-12 10:23:14 +0000" MODIFIED_BY="Christopher J Cates">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-01-08 13:50:56 +0000" MODIFIED_BY="Christopher J Cates" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Adults, outcome: 1.2 Number of people with acute respiratory exacerbation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA2gAAAGgCAMAAADo7LT/AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Rx group risk.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-01-12 10:23:14 +0000" MODIFIED_BY="Christopher J Cates" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Cates plot for NNT (B) over 2-years in reduction of infective exacerbation comparing PV23 vaccination to control in adults with chronic lung disease</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAhcAAAGLCAIAAAD79ye6AABuHklEQVR42uy9C1RU19n/v8+ZM1cY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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-01-07 15:45:20 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-01-07 15:45:20 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-01-07 15:29:10 +0000" MODIFIED_BY="[Empty name]">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2009-01-07 15:45:20 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="5">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Search keywords</P>
</TH>
</TR>
<TR>
<TD>
<P>AIRWAYS REGISTER</P>
</TD>
<TD>
<P>(bronchiectasis OR "suppurative lung disease") AND ((vaccin* OR immunis*) AND (pneum*))<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>CENTRAL</P>
</TD>
<TD>
<P>#1 MeSH descriptor Bronchiectasis explode all trees<BR/>#2 bronchiect*<BR/>#3 suppurativ* near lung*<BR/>#4 MeSH descriptor Ciliary Motility Disorders explode all trees<BR/>#5 ciliary near dyskinesia<BR/>#6 kartagener*<BR/>#7 (#1 OR #2 OR #3 OR #4 OR #5 OR #6)<BR/>#8 MeSH descriptor Pneumococcal Infections explode all trees<BR/>#9 pneum*<BR/>#10 MeSH descriptor Immunization explode all trees<BR/>#11 MeSH descriptor Vaccines explode all trees<BR/>#12 immuni*<BR/>#13 vaccinat*<BR/>#14 (#8 OR #9)<BR/>#15 (#10 OR #11 OR #12 OR #13)<BR/>#16 (#14 AND #15)<BR/>#17(#16 AND #7)<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE and OLDMEDLINE <BR/>
<BR/>(Combined with RCT filter)</P>
</TD>
<TD>
<P>1. exp Bronchiectasis/<BR/>2. bronchiect$.mp.<BR/>3. (bronch$ adj5 dilat$).mp.<BR/>4. (suppurativ$ adj5 lung$).mp.<BR/>5. (ciliary adj3 dyskinesia).mp.<BR/>6. kartagener$.mp.<BR/>7. or/1-6<BR/>8. exp Pneumococcal Infections/<BR/>9. pneum$.mp.<BR/>10. exp Immunization/<BR/>11. exp Vaccines/<BR/>12. vaccinat$.mp.<BR/>13. immuni$.mp.<BR/>14. (or/8-9) and (or/10-13)<BR/>15. (pneumoc$ adj5 vaccin$).mp.<BR/>16. (pneumoc$ adj5 immuni$).mp.<BR/>17. pneumococcal vaccines/<BR/>18. or/14-17<BR/>19. 18 and 7<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE <BR/>
<BR/>(Combined with RCT filter)</P>
</TD>
<TD>
<P>1. exp Bronchiectasis/<BR/>2. bronchiect$.mp.<BR/>3. (bronch$ adj5 dilat$).mp.<BR/>4. (suppurativ$ adj5 lung$).mp.<BR/>5. (ciliary adj3 dyskinesia).mp.<BR/>6. kartagener$.mp.<BR/>7. or/1-6<BR/>8. exp Pneumococcal Infections/<BR/>9. pneum$.mp.<BR/>10. exp Immunization/<BR/>11. exp Vaccines/<BR/>12. vaccinat$.mp.<BR/>13. immuni$.mp.<BR/>14. (or/8-9) and (or/10-13)<BR/>15. (pneumoc$ adj5 vaccin$).mp.<BR/>16. (pneumoc$ adj5 immuni$).mp.<BR/>17. pneumococcal vaccines/<BR/>18. or/14-17<BR/>19. 18 and 7<BR/>
<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>